Indoco Remedies sees a credit rating action
TL;DR
What is the specific revenue contribution of the Goa sterile facility to Indoco’s total US formulations business, and what percentage of the company's pending ANDA pipeline is currently manufactured or slated for production at this specific site?
I couldn't find relevant information for this query. Please try rephrasing or asking about a specific metric.
How does the current regulatory status of the Goa facility compare to the remediation timelines and associated compliance cost spikes reported by peer mid-cap Indian pharma companies that have faced similar Form 483 observations in the last 24 months?
Verdict: Indoco’s Goa facility is at the initial observation-and-response stage, not yet at a documented remediation-completion or reinspection stage. The 5 September 2026 disclosure records seven Form 483 observations after the 27 August–4 September inspection and says the company is preparing a response within the stipulated timeframe; it gives no remediation deadline, CAPA completion date, reinspection status, or quantified compliance cost. [2]
Goa facility: current status
- Facility: Plant II (Sterile), Goa. [2]
- Inspection: 27 August–4 September 2026. [2]
- Outcome: Seven Form 483 observations. [2]
- Management action: Comprehensive response being prepared for submission within the stipulated timeframe. [2]
- Remediation timeline: Not disclosed beyond the response window. [2]
- Compliance cost: No incremental remediation or compliance-cost estimate disclosed. [2]
- Regulatory outcome: No CAPA closure, follow-up inspection, warning-letter status, import alert, or product-supply impact is reported in the disclosure. [2]
Peer comparison
Fredun Pharmaceuticals: No cited disclosure establishes a comparable Form 483 event, remediation duration, or compliance-cost spike for the requested period.
Beta Drugs: No cited disclosure establishes a comparable Form 483 event, remediation duration, or compliance-cost spike for the requested period.
Windlas Biotech: No cited disclosure establishes a comparable Form 483 event, remediation duration, or compliance-cost spike for the requested period.
Panacea Biotec: No cited disclosure establishes a comparable Form 483 event, remediation duration, or compliance-cost spike for the requested period.
Sai Parenterals: No cited disclosure establishes a comparable Form 483 event, remediation duration, or compliance-cost spike for the requested period.
Analytical read
The only defensible comparison is therefore process-stage based, not timeline- or cost-based:
- Indoco: observations issued; formal response underway.
- Peer remediation timelines: not established by cited evidence.
- Peer compliance-cost spikes: not established by cited evidence.
- Indoco cost exposure: currently unquantified, so no evidence supports extrapolating a peer-style cost spike.
The key next disclosures would be Indoco’s response submission, the scope of corrective and preventive actions, any production or shipment restrictions, an estimated remediation budget, and the outcome or timing of a USFDA follow-up inspection. News and analyst coverage for the peer comparison was not available, so a quantified 24-month peer benchmark would be unsupported.
Sources
- [1]Depreciation
- [2]Indoco Remedies receives 7 USFDA Form 483 observations for Goa sterile facility. — 2026-09-05T13:37:49, p.1
Keep digging
